Details

Autor(en) / Beteiligte

• Florida, Elizabeth M
• Li, Haiou
• Hong, Christin G
• Ongstad, Emily L
• Gaddipati, Ranjitha
• Sitaula, Sadichha
• Varma, Vijayalakshmi
• Parel, Philip M
• O'Hagan, Ross
• Chen, Marcus Y
• Teague, Heather L
• Playford, Martin P
• Karathanasis, Sotirios K
• Collén, Anna
• Mehta, Nehal N
• Remaley, Alan T
• Sorokin, Alexander V

Titel

Relationship of Soluble Lectin-Like Low-Density Lipoprotein Receptor-1 (sLOX-1) With Inflammation and Coronary Plaque Progression in Psoriasis

Ist Teil von

• Journal of the American Heart Association, 2023-11, Vol.12 (22), p.e031227-e031227

Ort / Verlag

England: John Wiley and Sons Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Psoriasis is a chronic inflammatory condition associated with coronary artery disease risk. Uptake of oxidized low-density lipoprotein by the lectin-like low-density lipoprotein receptor-1 triggers release of the soluble extracellular domain of the receptor (sLOX-1). We sought to characterize the relationship between sLOX-1, inflammation, and coronary plaque progression in psoriasis. A total of 327 patients with psoriasis had serum sLOX-1 levels measured at baseline by an ELISA-based assay. Stratification by high-sensitivity C-reactive protein ≥4.0 mg/L (quartile 4), identified 81 participants who had coronary plaque phenotyping at baseline and were followed longitudinally by coronary computed tomography angiography. Subjects within high-sensitivity C-reactive protein quartile 4 were middle-aged (51.47±12.62 years), predominantly men (54.3%) with moderate psoriasis disease severity (6.60 [interquartile range, 3.30-13.40]). In the study cohort, participants with sLOX-1 above the median displayed increased vulnerable coronary plaque features. At baseline, sLOX-1 was associated with total burden (rho=0.296; =0.01), noncalcified burden (rho=0.286; =0.02), fibro-fatty burden (rho=0.346; =0.004), and necrotic burden (rho=0.394; =0.002). A strong relationship between sLOX-1, noncalcified burden ( =0.19; =0.03), and fibro-fatty burden ( =0.29; =0.003) was found in fully adjusted models at baseline and 1- and 4-year follow-up. Finally, coronary plaque features progressed over 1 year regardless of biologic or systemic treatment in subjects with high sLOX-1. Patients with psoriasis with both high sLOX-1 and high-sensitivity C-reactive protein levels have increased coronary plaque burden associated with atherosclerotic plaque progression independent of biologic and systemic treatment. Thus, sLOX-1 might be considered as a promising marker in coronary artery disease risk estimation beyond traditional risk factors. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01778569.